1. 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. (September 2015) Authors: Rini, B.; Stenzl, A.; Zdrojowy, R.; Kogan, M.; Shkolnik, M.; Oudard, S.; Weikert, S.; Bracarda, S.; Crabb, S.; Bedke, J.; Ludwig, J.; Maurer, D.; Mendrzyk, R.; Mahr, A.; Fritsche, J.; Weinschenk, T.; Singh, H.; Kirner, A.; Reinhardt, C.; Eisen, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S718 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CTLA‐4 and CD28 genes' polymorphisms and renal cell carcinoma susceptibility in the Polish population – a prospective study. Issue 5 (25th September 2015) Authors: Tupikowski, K.; Partyka, A.; Kolodziej, A.; Dembowski, J.; Debinski, P.; Halon, A.; Zdrojowy, R.; Frydecka, I.; Karabon, L. Journal: Tissue antigens Issue: Volume 86:Issue 5(2015) Page Start: 353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Uroplakin IIIa Is a Marker in Bladder Cancer but Seems Not to Reflect Chemical Carcinogenesis. (5th July 2018) Authors: Szymańska, B.; Matuszewski, M.; Dembowski, J.; Zdrojowy, R.; Długosz, A. Other Names: Rao Jianyu Y. Academic Editor. Journal: BioMed research international Issue: Volume 2018(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗